refer to descriptions included in the company's filings with the securities and exchange commission for more information about the company. the company does not intend to update and does not take responsibility for any information published on linkedin.
Company profile
Ticker
SAVA
Exchange
Website
CEO
Remi Barbier
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
PAIN THERAPEUTICS INC
SEC CIK
Corporate docs
Subsidiaries
Austin Innovation Park, LLC ...
IRS number
911911336
SAVA stock data
Latest filings (excl ownership)
DEF 14A
Definitive proxy
26 Mar 24
ARS
2023 FY
Annual report to shareholders
22 Mar 24
10-K
2023 FY
Annual report
28 Feb 24
8-K
Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates
28 Feb 24
8-K
No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months
7 Feb 24
CERT
Certification of approval for exchange listing
3 Jan 24
424B2
Prospectus for primary offering
3 Jan 24
8-A12B
Registration of securities on exchange
3 Jan 24
8-K
Entry into a Material Definitive Agreement
3 Jan 24
8-A12G
Registration of securities
2 Jan 24
Transcripts
Latest ownership filings
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
BARBIER REMI
1 Feb 24
SC 13G/A
BlackRock Inc.
26 Jan 24
4
Claude Nicaise
8 Dec 23
3
Claude Nicaise
8 Dec 23
4
Pierre Gravier
7 Dec 23
4
Robert Eugene Anderson Jr
7 Dec 23
3
Pierre Gravier
7 Dec 23
3
Robert Eugene Anderson Jr
7 Dec 23
4
Eric Schoen
4 Oct 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 142.35 mm | 142.35 mm | 142.35 mm | 142.35 mm | 142.35 mm | 142.35 mm |
Cash burn (monthly) | 8.70 mm | 2.69 mm | 9.29 mm | 8.68 mm | 8.84 mm | 6.75 mm |
Cash used (since last report) | 51.85 mm | 16.06 mm | 55.41 mm | 51.73 mm | 52.73 mm | 40.26 mm |
Cash remaining | 90.50 mm | 126.29 mm | 86.94 mm | 90.62 mm | 89.62 mm | 102.09 mm |
Runway (months of cash) | 10.4 | 46.9 | 9.4 | 10.4 | 10.1 | 15.1 |
Institutional ownership, Q3 2023
29.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 142 |
Opened positions | 19 |
Closed positions | 24 |
Increased positions | 55 |
Reduced positions | 30 |
13F shares | Current |
---|---|
Total value | 204.66 bn |
Total shares | 12.72 mm |
Total puts | 2.53 mm |
Total calls | 2.72 mm |
Total put/call ratio | 0.9 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 2.84 mm | $47.24 bn |
Vanguard | 2.27 mm | $37.75 bn |
STT State Street | 1.03 mm | $17.07 bn |
Geode Capital Management | 830.25 k | $13.82 bn |
BAC Bank Of America | 621.80 k | $10.35 bn |
Gallacher Capital Management | 577.82 k | $9.61 bn |
MS Morgan Stanley | 433.24 k | $7.21 bn |
NTRS Northern Trust | 373.63 k | $6.22 bn |
Charles Schwab Investment Management | 304.72 k | $5.07 bn |
SG Americas Securities | 276.43 k | $4.60 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
6 Dec 23 | Robert Eugene Anderson Jr | Stock Option Common Stock | Grant | Acquire A | No | No | 21.71 | 20,000 | 434.20 k | 20,000 |
6 Dec 23 | Pierre Gravier | Stock Option Common Stock | Grant | Acquire A | No | No | 21.71 | 20,000 | 434.20 k | 20,000 |
News
Cassava Sciences Completes Interim Safety Review Of Oral Simufilam On-Going Phase 3 Trials
25 Mar 24
(SAVA) - Analyzing Cassava Sciences's Short Interest
21 Mar 24
Alzheimer's Drug Trial Results Questioned After 'Damning' FDA Inspection Report
11 Mar 24
Boeing, Oracle, Meta Platforms, Cassava Sciences, Tesla: Why These 5 Stocks Are On Investors' Radars Today
11 Mar 24
HC Wainwright & Co. Reiterates Buy on Cassava Sciences, Maintains $124 Price Target
5 Mar 24
Press releases
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava
28 Mar 24
ROSEN, A LONGSTANDING LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important April 2 Deadline in Securities Class Action - SAVA
27 Mar 24
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAVA
27 Mar 24
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cassava, NYCB, Amylyx, and InMode and Encourages Investors to Contact the Firm
25 Mar 24
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
25 Mar 24